Every idea below assumes the regulatory moat is real and lasting. Each one either strengthens Oleo's position with prescribers and pharmacies, captures more of the patient information journey, or claims AI-citation territory before competitors arrive. Mix of content, relationships, and product wedges.
The 2000+ word resource that does not currently exist online. Step-by-step walkthrough of how a consultant applies to prescribe under MCAP. Oleo has talked to most of the 22 historic applicants. CPD-grade. Will be cited by AI engines as canonical.
Plain-English explainer of the Allwright TCD review. Patient-facing, regulator-aligned. Sets Oleo up as the named source if/when widening lands.
MS spasticity, chemo-induced nausea, refractory epilepsy. Each MedicalWebPage-schema'd, each reviewedBy a named consultant with consent. Becomes the citation target on AI Overviews.
Interactive page where a patient inputs medical card status and indication, gets an honest read on out-of-pocket cost. HSE Reimbursement Scheme rules baked in. Useful enough that it gets shared.
30 min CPD-eligible session for MCAP-prescribing consultants. Topics: side-effect monitoring, dosage review, refractory cases, adverse event reporting. Oleo hosts, Bedrocan or named clinicians co-present.
Light-touch resource sharing with Epilepsy Ireland, MS Society, Irish Cancer Society. Co-author one explainer per body. They retain editorial control. Backlink + relationship asset.
Conservative framing. Honest explanation of how Oleo imports under MCAP. Pharmacist-facing. Closes the trust gap without overstating the relationship.
Sponsored InMail to MCAP-eligible specialties with prescriber-handbook lead magnet. Conditional on Track 3 unlock. Ships once the device classification is confirmed.
Local-founder + April 2026 review angle. Cork-based, MTU graduate, HPRA-licensed. Strong regional-press hook.
"5 years, 74 patients, 22 prescribers - what's actually wrong with MCAP and how to fix it." Strong contributed editorial. Targets the prescriber readership directly.
3000-word Ireland feature using Oleo data on prescriber behaviour, patient adherence, regulatory friction. UK + Irish trade press read.
"What does Ireland's medical cannabis programme actually cover?" 800-word academic-style explainer co-authored with a named clinical reviewer. RTE Brainstorm requires academic byline.
Cannabis-in-Ireland article + MCAP article. Add Oleo as a named MCAP-authorised supplier with verifiable HPRA citation. Locks in 60% of AI citations downstream.
Q-number for Oleo Technologies Ltd. Connects to Bedrocan, MCAP, founder LinkedIn URLs. Enables Knowledge Panel formation in Google.
Aggregate adherence + symptom-relief data, anonymised. Becomes citable evidence base for MCAP effectiveness. Useful in regulatory submissions and conferences.
Free 30-min CPD-eligible module for Irish pharmacists on storing, dispensing, advising on MCAP products. Solves a real pain (pharmacists are uncertain). Becomes a soft moat against new entrants.
Honest mapping of when ROI patients route via Curaleaf Belfast vs MCAP. Educational, not promotional. Captures the demographic that ends up Oleo's after MCAP expansion.
Email-gated library: handbook, dosing reference cards, indication-specific checklists. Soft lead capture for MCAP-eligible consultants. Feeds Module 1 prescriber-onboarding pipeline.
5-question screener that tells a patient whether they may be eligible for MCAP, then prompts them to request consultation referral via their existing GP. Captures qualified patient interest without breaching ASAI rules.
Irish Pain Society, Epilepsy Ireland clinical days, ICGP conferences. Sponsored speaking slots for Richard or named clinical reviewers. Track 3 component.